Species differences in oral bioavailability of methotrexate between rats and monkeys

Biological and Pharmaceutical Bulletin

Volumn 23, Issue 3, 2000, Pages 334-338

  Kuroda, Toyoshi ^a   Namba, Kinya ^a   Torimaru, Tomoko ^a   Kawashima, Kosuke ^a   Hayashi, Masahiro ^b  

^a Lederle (Japan) Ltd   (Japan)

^b TOKYO UNIVERSITY OF SCIENCE   (Japan)

Author keywords

7 hydroxymethotrexate; Bioavailability; Methotrexate; Monkey; Pharmacokinetics; Rat

Indexed keywords

ALDEHYDE OXIDASE; METHOTREXATE;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG ELIMINATION; ENZYME ACTIVITY; FIRST PASS EFFECT; MALE; MONKEY; NONHUMAN; RAT; SPECIES DIFFERENCE;

EID: 0034071009     PISSN: 09186158     EISSN: None     Source Type: Journal    
DOI: 10.1248/bpb.23.334     Document Type: Article

References (30)

1. Jolivet J., Cowan K. H., Curt G. A., Clendeninn N. J., Chabner B. A., N. Engl. J. Med., 309, 1094-1104 (1983).
2. Weinstein G. D., Ann. Intern. Med., 86, 199-204 (1977).
3. Gispen J. G., Alarcon G. S., Johnson J. J., Acton R. T., Barger B. O., Koopman W. J., J. Rheumatol., 14, 74-79 (1987).
4. Weinblatt M. E., Trentham D. E., Fraser P. A., Holdsworth D. E., Falchuk K. R., Weissman B. N., Coblyn J. S., Arthritis Rheum., 31, 167-175 (1988).
5. Kremer J. M., Lee J. K., Arthritis Rheum., 31, 577-584 (1988).
6. Oguey D., Kölliker F., Gerber N. J., Reichen J., Arthritis Rheum., 35, 611-614 (1992).
7. Lebbe C., Beyeler C., Gerber N. J., Reichen J., Ann. Rheum. Dis., 53, 475-477 (1994).
8. Hamilton R. A., Kremer J. M., J. Rheumatol., 22, 630-632 (1995).
9. Murry D. J., Synold T. W., Pui C. H., Rodman J. H., Pharmacother., 15, 144-149 (1995).
10. Jacobs S. A., Stoller R. G., Chabner B. A., Johns D. G., J. Clin. Invest., 57, 534-538 (1976).
11. Dhondt J. L., Hayte J. M., Millot F., Klein R., Blais J. C., Pfleiderer W., Eur. J. Biochem., 200, 237-244 (1991).
12. Huh K., Yamamoto I., Gohda E., Iwata H., Jpn. J. Pharmacol., 26, 719-724 (1976).
13. Beedham C., Bruce S. E., Critchley D. J., Al-Tayib Y., Rance D. J., Eur. J. Drug Metab. Pharmacokin., 12, 307-310 (1987).
14. Sugihara K., Kitamura S., Tatsumi K., Biochem. Molecul. Biol. Intern., 37, 861-869 (1995).
15. Kawashima K., Hosoi K., Naruke T., Shiba T., Kitamura M., Watabe T., Drug Metab. Dispos., 27, 422-428 (1999).
16. Kawashima K., Hosoi K., Tainaka H., Nakazawa T., Shiba T., Kishi I., Hiratsuka A., Watabe T., Xenobio. Metabol. Dispos., 11, S163 (1996).
17. Kinouchi T., Kataoka K., Miyanishi K., Akimoto S., Ohnishi Y., Carcinogenesis, 14, 869-874 (1993).
18. Beck O., Seideman P., Wennberg M., Peterson C., Ther. Drug Monit., 13, 528-532 (1991).
19. Kuroda T., Yoshizawa N., Nakazawa T., Torimaru T., Naruke T., Wyeth Lederele Japan Company Report, unpublished.
20. Lin J. H., Sugiyama Y., Awazu S., Hanano M., J. Pharmacokin. Biopharm., 10, 649-661 (1982).
21. Mordenti J., J. Pharm. Sci., 75, 1028-1040 (1986).
22. Ichimura F., Yokogawa K., Yamana T., Tsuji A., Yamamoto K., Murakami S., Mizukami Y., Int. J. Pharm., 19, 75-88 (1984).
23. Zimmerman J., Biochem. Pharmacol. 43, 2377-2383 (1992).
24. Hunter J., Hirst B. H., Adv. Drug Deliv. Rev., 25, 129-157 (1997).
25. Mitsuoka T., Kaneuchi C., Am. J. Clin. Nutr., 30, 1799-1810 (1977).
26. Mitsuoka T., "Intestinal Flora and Cancer 2," Japan Scientific Societies Press, Tokyo, 1995, pp. 3-27.
27. Ahern M., Booth J., Loxton A., McCarthy P., Meffin P., Kevat S,. J. Rheumatol., 15, 1356-1360 (1988).
28. Shen D. D., Azarnoff D. L., Clin. Pharmacokin., 3, 1-13 (1978).
29. Wan S. H., Huffman D. H., Azarnoff D. L., Stephens R., Hoogstraten B., Cancer Res., 34, 3487-3491 (1974).
30. Smith D. K., Omura G. A., Ostroy F., Cancer Chemother. Pharmacol., 4, 117-120 (1980).